Assessment of the efficacy of Lanreotide Autogel® in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegaly
Not Applicable
Completed
- Conditions
- Acromegaly and medical pre treatment with Lanreotide Autogel®Nutritional, Metabolic, EndocrineAcromegaly and pituitary gigantism
- Registration Number
- ISRCTN20365485
- Lead Sponsor
- Addenbrooke's NHS Trust R&D
- Brief Summary
2013 results in: https://www.ncbi.nlm.nih.gov/pubmed/23393175
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1. Treatment naive newly diagnosed subjects with biochemically confirmed acromegaly
2. Males and females
3. More than 18 years of age
Exclusion Criteria
Subjects who had prior medical therapy, surgery or radiotherapy or sight-threatening tumours requiring urgent surgical decompression
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method